Wei Perng
Concepts (433)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiposity | 38 | 2026 | 533 | 9.150 |
Why?
| | Prenatal Exposure Delayed Effects | 25 | 2026 | 665 | 6.570 |
Why?
| | Pediatric Obesity | 19 | 2026 | 635 | 4.690 |
Why?
| | Body Mass Index | 57 | 2026 | 2458 | 4.580 |
Why?
| | Metabolomics | 17 | 2026 | 738 | 3.420 |
Why?
| | Diabetes, Gestational | 12 | 2025 | 307 | 3.220 |
Why?
| | Environmental Pollutants | 11 | 2026 | 143 | 3.120 |
Why?
| | Diet | 22 | 2026 | 1273 | 3.090 |
Why?
| | Pregnancy | 77 | 2026 | 7230 | 2.980 |
Why?
| | Cardiovascular Diseases | 16 | 2026 | 2219 | 2.930 |
Why?
| | Birth Weight | 20 | 2026 | 521 | 2.770 |
Why?
| | Biomarkers | 36 | 2026 | 4340 | 2.610 |
Why?
| | Non-alcoholic Fatty Liver Disease | 8 | 2023 | 265 | 2.370 |
Why?
| | Weight Gain | 12 | 2026 | 562 | 2.330 |
Why?
| | Polycystic Ovary Syndrome | 7 | 2026 | 191 | 2.330 |
Why?
| | Child | 93 | 2026 | 22693 | 2.160 |
Why?
| | DNA Methylation | 12 | 2024 | 725 | 1.970 |
Why?
| | Child Health | 7 | 2026 | 153 | 1.950 |
Why?
| | Epigenesis, Genetic | 11 | 2025 | 712 | 1.930 |
Why?
| | Obesity | 27 | 2026 | 3131 | 1.920 |
Why?
| | Insulin | 11 | 2026 | 2525 | 1.860 |
Why?
| | Female | 142 | 2026 | 79499 | 1.830 |
Why?
| | Leptin | 10 | 2024 | 248 | 1.810 |
Why?
| | Body Composition | 15 | 2023 | 689 | 1.800 |
Why?
| | Endocrine Disruptors | 4 | 2024 | 42 | 1.790 |
Why?
| | Environmental Exposure | 9 | 2026 | 578 | 1.760 |
Why?
| | Mothers | 10 | 2025 | 772 | 1.660 |
Why?
| | Child, Preschool | 53 | 2026 | 11913 | 1.550 |
Why?
| | Prospective Studies | 39 | 2026 | 8123 | 1.530 |
Why?
| | Adolescent | 62 | 2026 | 22557 | 1.520 |
Why?
| | Humans | 165 | 2026 | 146342 | 1.520 |
Why?
| | Metabolic Syndrome | 5 | 2021 | 364 | 1.500 |
Why?
| | Metabolome | 8 | 2026 | 390 | 1.480 |
Why?
| | Premature Birth | 9 | 2026 | 390 | 1.470 |
Why?
| | Inflammation | 8 | 2026 | 2919 | 1.420 |
Why?
| | Infant, Newborn | 38 | 2026 | 6460 | 1.410 |
Why?
| | Maternal Nutritional Physiological Phenomena | 7 | 2026 | 178 | 1.400 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2025 | 2623 | 1.390 |
Why?
| | Overnutrition | 3 | 2021 | 28 | 1.390 |
Why?
| | Hypertension, Pregnancy-Induced | 6 | 2025 | 69 | 1.380 |
Why?
| | Pregnancy Outcome | 7 | 2026 | 503 | 1.380 |
Why?
| | Body Weight | 7 | 2022 | 968 | 1.330 |
Why?
| | Waist Circumference | 11 | 2026 | 142 | 1.300 |
Why?
| | Overweight | 8 | 2024 | 614 | 1.290 |
Why?
| | Insulin Resistance | 13 | 2026 | 1247 | 1.280 |
Why?
| | Cohort Studies | 31 | 2026 | 6077 | 1.270 |
Why?
| | Stress, Psychological | 3 | 2023 | 1171 | 1.220 |
Why?
| | Fatty Liver | 4 | 2026 | 252 | 1.210 |
Why?
| | Fruit and Vegetable Juices | 2 | 2026 | 23 | 1.180 |
Why?
| | Placenta | 4 | 2026 | 794 | 1.160 |
Why?
| | Body Height | 5 | 2018 | 205 | 1.140 |
Why?
| | Male | 82 | 2026 | 73396 | 1.140 |
Why?
| | Blood Pressure | 11 | 2025 | 1765 | 1.140 |
Why?
| | Blood Glucose | 13 | 2026 | 2360 | 1.130 |
Why?
| | Long Interspersed Nucleotide Elements | 3 | 2013 | 36 | 1.130 |
Why?
| | Fetal Blood | 6 | 2024 | 325 | 1.130 |
Why?
| | Risk Factors | 28 | 2025 | 10921 | 1.120 |
Why?
| | Health Status | 3 | 2024 | 827 | 1.110 |
Why?
| | Nutritional Status | 5 | 2026 | 346 | 1.090 |
Why?
| | C-Reactive Protein | 10 | 2026 | 429 | 1.080 |
Why?
| | Feeding Behavior | 4 | 2026 | 692 | 1.070 |
Why?
| | Fluorocarbons | 3 | 2025 | 122 | 1.020 |
Why?
| | Adult | 55 | 2026 | 41087 | 1.010 |
Why?
| | Child Development | 8 | 2026 | 481 | 0.970 |
Why?
| | Young Adult | 30 | 2026 | 14330 | 0.960 |
Why?
| | Lipase | 2 | 2026 | 76 | 0.940 |
Why?
| | Anti-Mullerian Hormone | 2 | 2025 | 62 | 0.940 |
Why?
| | Metabolic Diseases | 4 | 2021 | 114 | 0.930 |
Why?
| | Beverages | 1 | 2026 | 67 | 0.920 |
Why?
| | Adiponectin | 6 | 2025 | 243 | 0.910 |
Why?
| | Amino Acids, Branched-Chain | 4 | 2022 | 39 | 0.900 |
Why?
| | Puberty | 4 | 2022 | 141 | 0.900 |
Why?
| | Mexico | 11 | 2023 | 233 | 0.890 |
Why?
| | Maternal Exposure | 5 | 2025 | 189 | 0.890 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2026 | 455 | 0.880 |
Why?
| | Phthalic Acids | 3 | 2024 | 43 | 0.870 |
Why?
| | Diabetic Neuropathies | 1 | 2025 | 101 | 0.830 |
Why?
| | Skinfold Thickness | 4 | 2018 | 43 | 0.810 |
Why?
| | Diabetic Angiopathies | 1 | 2025 | 265 | 0.780 |
Why?
| | Longitudinal Studies | 20 | 2026 | 3017 | 0.750 |
Why?
| | Menopause | 6 | 2026 | 328 | 0.750 |
Why?
| | Psychological Tests | 1 | 2023 | 127 | 0.740 |
Why?
| | Lead | 2 | 2021 | 71 | 0.730 |
Why?
| | Liver | 4 | 2026 | 1864 | 0.730 |
Why?
| | Genotype | 3 | 2026 | 1879 | 0.730 |
Why?
| | Massachusetts | 8 | 2026 | 178 | 0.730 |
Why?
| | Sexual Maturation | 2 | 2019 | 49 | 0.720 |
Why?
| | Self Report | 4 | 2023 | 870 | 0.700 |
Why?
| | Pregnancy Proteins | 1 | 2022 | 36 | 0.700 |
Why?
| | Azocines | 1 | 2021 | 8 | 0.700 |
Why?
| | Diabetic Nephropathies | 1 | 2025 | 320 | 0.690 |
Why?
| | Hyaenidae | 1 | 2021 | 4 | 0.680 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.680 |
Why?
| | Infant | 29 | 2026 | 10114 | 0.680 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.680 |
Why?
| | Ecology | 1 | 2022 | 106 | 0.680 |
Why?
| | Breast Feeding | 6 | 2026 | 447 | 0.670 |
Why?
| | Maternal Behavior | 1 | 2021 | 83 | 0.650 |
Why?
| | Biological Evolution | 2 | 2022 | 471 | 0.640 |
Why?
| | Lipid Metabolism | 1 | 2024 | 533 | 0.630 |
Why?
| | Hyperinsulinism | 1 | 2021 | 115 | 0.630 |
Why?
| | Triglycerides | 7 | 2023 | 527 | 0.620 |
Why?
| | Membrane Proteins | 2 | 2026 | 1130 | 0.620 |
Why?
| | Racism | 1 | 2022 | 147 | 0.600 |
Why?
| | Prediabetic State | 1 | 2023 | 250 | 0.600 |
Why?
| | Socioeconomic Factors | 10 | 2026 | 1327 | 0.600 |
Why?
| | Social Environment | 1 | 2021 | 246 | 0.600 |
Why?
| | Residence Characteristics | 4 | 2026 | 385 | 0.590 |
Why?
| | Islets of Langerhans | 2 | 2023 | 852 | 0.560 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.560 |
Why?
| | Hypertension | 4 | 2025 | 1272 | 0.550 |
Why?
| | Lipids | 3 | 2020 | 714 | 0.540 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2018 | 72 | 0.540 |
Why?
| | Linear Models | 8 | 2024 | 857 | 0.530 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2018 | 47 | 0.530 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2018 | 14 | 0.530 |
Why?
| | Postpartum Period | 4 | 2026 | 377 | 0.530 |
Why?
| | Cholesterol | 4 | 2023 | 411 | 0.520 |
Why?
| | Adipose Tissue | 5 | 2020 | 642 | 0.520 |
Why?
| | Body Fluid Compartments | 1 | 2017 | 6 | 0.520 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2017 | 24 | 0.520 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 32 | 0.520 |
Why?
| | Homeostasis | 2 | 2021 | 646 | 0.510 |
Why?
| | Adipokines | 3 | 2026 | 56 | 0.500 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2018 | 145 | 0.490 |
Why?
| | Sex Characteristics | 2 | 2020 | 801 | 0.490 |
Why?
| | Bone and Bones | 1 | 2019 | 319 | 0.480 |
Why?
| | Androgens | 1 | 2018 | 179 | 0.480 |
Why?
| | Gestational Age | 5 | 2026 | 990 | 0.470 |
Why?
| | MicroRNAs | 1 | 2022 | 699 | 0.470 |
Why?
| | Anthropometry | 6 | 2022 | 204 | 0.460 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5439 | 0.460 |
Why?
| | Interleukin-6 | 5 | 2026 | 784 | 0.450 |
Why?
| | Fetal Development | 1 | 2018 | 297 | 0.440 |
Why?
| | Signal Transduction | 3 | 2026 | 5246 | 0.440 |
Why?
| | Micronutrients | 2 | 2013 | 102 | 0.440 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 320 | 0.430 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1101 | 0.430 |
Why?
| | alpha-Linolenic Acid | 1 | 2014 | 8 | 0.430 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2025 | 88 | 0.430 |
Why?
| | Maternal Welfare | 1 | 2014 | 22 | 0.430 |
Why?
| | Colombia | 6 | 2018 | 41 | 0.420 |
Why?
| | Carbon Isotopes | 2 | 2025 | 143 | 0.420 |
Why?
| | Choline | 2 | 2025 | 136 | 0.410 |
Why?
| | Hyperhomocysteinemia | 1 | 2013 | 26 | 0.400 |
Why?
| | Alu Elements | 1 | 2013 | 28 | 0.400 |
Why?
| | Air Pollution | 3 | 2025 | 314 | 0.390 |
Why?
| | Abdominal Fat | 3 | 2023 | 51 | 0.390 |
Why?
| | Homocysteine | 1 | 2013 | 152 | 0.380 |
Why?
| | Iron, Dietary | 1 | 2013 | 23 | 0.380 |
Why?
| | Age Factors | 6 | 2025 | 3347 | 0.370 |
Why?
| | Air Pollutants | 3 | 2025 | 406 | 0.370 |
Why?
| | Sex Factors | 5 | 2026 | 2107 | 0.370 |
Why?
| | Intra-Abdominal Fat | 3 | 2023 | 104 | 0.370 |
Why?
| | Growth Disorders | 1 | 2013 | 89 | 0.360 |
Why?
| | Fatty Acids | 2 | 2020 | 460 | 0.360 |
Why?
| | Endotoxins | 2 | 2023 | 215 | 0.360 |
Why?
| | Poliomyelitis | 1 | 2012 | 35 | 0.350 |
Why?
| | Infertility | 2 | 2022 | 62 | 0.350 |
Why?
| | American Heart Association | 2 | 2024 | 364 | 0.350 |
Why?
| | Health Behavior | 4 | 2024 | 802 | 0.340 |
Why?
| | Diseases in Twins | 1 | 2012 | 115 | 0.340 |
Why?
| | Food Hypersensitivity | 2 | 2024 | 165 | 0.330 |
Why?
| | Twins | 1 | 2012 | 156 | 0.330 |
Why?
| | Milk, Human | 2 | 2026 | 176 | 0.330 |
Why?
| | Nutrition Policy | 2 | 2026 | 56 | 0.330 |
Why?
| | Boston | 4 | 2025 | 90 | 0.320 |
Why?
| | Causality | 2 | 2021 | 128 | 0.300 |
Why?
| | Atherosclerosis | 1 | 2013 | 410 | 0.300 |
Why?
| | Logistic Models | 4 | 2025 | 2126 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5899 | 0.290 |
Why?
| | Age of Onset | 2 | 2022 | 558 | 0.290 |
Why?
| | Middle Aged | 16 | 2026 | 36619 | 0.290 |
Why?
| | C-Peptide | 2 | 2021 | 191 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3930 | 0.290 |
Why?
| | United States | 11 | 2026 | 16136 | 0.280 |
Why?
| | Phospholipases A2, Calcium-Independent | 2 | 2026 | 18 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2026 | 1224 | 0.280 |
Why?
| | Exercise | 4 | 2025 | 2213 | 0.270 |
Why?
| | Acyltransferases | 2 | 2026 | 78 | 0.270 |
Why?
| | Principal Component Analysis | 3 | 2019 | 192 | 0.270 |
Why?
| | Child Care | 2 | 2024 | 32 | 0.260 |
Why?
| | Phenols | 2 | 2026 | 106 | 0.250 |
Why?
| | Infant, Small for Gestational Age | 3 | 2026 | 118 | 0.240 |
Why?
| | Alkanesulfonic Acids | 2 | 2025 | 37 | 0.230 |
Why?
| | Multivariate Analysis | 5 | 2016 | 1543 | 0.230 |
Why?
| | Nonprescription Drugs | 1 | 2026 | 68 | 0.230 |
Why?
| | Regression Analysis | 3 | 2018 | 999 | 0.230 |
Why?
| | Obesity, Abdominal | 1 | 2026 | 48 | 0.230 |
Why?
| | Thinness | 1 | 2026 | 100 | 0.230 |
Why?
| | Dietary Sugars | 1 | 2025 | 21 | 0.220 |
Why?
| | Odds Ratio | 3 | 2023 | 1077 | 0.220 |
Why?
| | Population Dynamics | 1 | 2026 | 142 | 0.220 |
Why?
| | Colorado | 5 | 2024 | 4595 | 0.220 |
Why?
| | Incidence | 3 | 2023 | 2936 | 0.210 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2026 | 129 | 0.210 |
Why?
| | Child Behavior | 2 | 2024 | 234 | 0.210 |
Why?
| | Asthma | 4 | 2023 | 1800 | 0.210 |
Why?
| | Absorptiometry, Photon | 3 | 2026 | 278 | 0.210 |
Why?
| | Parabens | 1 | 2024 | 11 | 0.210 |
Why?
| | Hyperglycemia | 2 | 2018 | 384 | 0.210 |
Why?
| | Hyperandrogenism | 1 | 2025 | 25 | 0.210 |
Why?
| | Genetic Association Studies | 2 | 2019 | 379 | 0.210 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1537 | 0.210 |
Why?
| | Prevalence | 3 | 2025 | 2861 | 0.200 |
Why?
| | Vulnerable Populations | 1 | 2025 | 178 | 0.200 |
Why?
| | Acetaminophen | 1 | 2026 | 268 | 0.200 |
Why?
| | Birth Order | 1 | 2023 | 15 | 0.200 |
Why?
| | Pregnancy Complications | 3 | 2020 | 609 | 0.190 |
Why?
| | Diabetic Retinopathy | 1 | 2025 | 211 | 0.190 |
Why?
| | Parturition | 2 | 2022 | 72 | 0.180 |
Why?
| | Immunoglobulin E | 1 | 2024 | 315 | 0.180 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2025 | 2240 | 0.180 |
Why?
| | Phenotype | 2 | 2022 | 3206 | 0.180 |
Why?
| | Vegetables | 2 | 2020 | 159 | 0.180 |
Why?
| | Cannabidiol | 1 | 2024 | 142 | 0.180 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 47 | 0.180 |
Why?
| | Adolescent Behavior | 2 | 2024 | 486 | 0.170 |
Why?
| | Amino Acids | 1 | 2026 | 515 | 0.170 |
Why?
| | Dronabinol | 1 | 2024 | 251 | 0.170 |
Why?
| | Plethysmography | 2 | 2022 | 104 | 0.170 |
Why?
| | Toxoplasmosis, Animal | 1 | 2021 | 8 | 0.170 |
Why?
| | Carbohydrates | 1 | 2021 | 66 | 0.170 |
Why?
| | Michigan | 2 | 2020 | 203 | 0.170 |
Why?
| | Cholesterol, LDL | 2 | 2022 | 363 | 0.170 |
Why?
| | Educational Status | 1 | 2023 | 466 | 0.170 |
Why?
| | Hand Strength | 1 | 2022 | 149 | 0.170 |
Why?
| | Lysine | 1 | 2024 | 303 | 0.170 |
Why?
| | Antibodies, Protozoan | 1 | 2021 | 41 | 0.170 |
Why?
| | Glucose Tolerance Test | 2 | 2025 | 360 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2023 | 522 | 0.170 |
Why?
| | Toxoplasma | 1 | 2021 | 50 | 0.160 |
Why?
| | Latin America | 1 | 2021 | 96 | 0.160 |
Why?
| | Dermatitis, Atopic | 1 | 2024 | 319 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2024 | 322 | 0.160 |
Why?
| | Cats | 1 | 2021 | 226 | 0.160 |
Why?
| | Protective Factors | 1 | 2021 | 97 | 0.160 |
Why?
| | Testosterone | 1 | 2025 | 419 | 0.160 |
Why?
| | Sarcopenia | 1 | 2022 | 100 | 0.160 |
Why?
| | Selection, Genetic | 1 | 2022 | 269 | 0.150 |
Why?
| | Pre-Eclampsia | 1 | 2022 | 206 | 0.150 |
Why?
| | Scotland | 1 | 2019 | 54 | 0.150 |
Why?
| | Problem Behavior | 1 | 2021 | 97 | 0.150 |
Why?
| | Precision Medicine | 1 | 2023 | 462 | 0.140 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 368 | 0.140 |
Why?
| | Health Surveys | 1 | 2021 | 511 | 0.140 |
Why?
| | Models, Theoretical | 1 | 2022 | 561 | 0.140 |
Why?
| | Acetylcarnitine | 1 | 2018 | 6 | 0.140 |
Why?
| | Aminoisobutyric Acids | 1 | 2018 | 9 | 0.140 |
Why?
| | Hydroxyproline | 1 | 2018 | 18 | 0.140 |
Why?
| | Fasting | 1 | 2020 | 280 | 0.140 |
Why?
| | Ornithine | 1 | 2018 | 28 | 0.140 |
Why?
| | Infant, Premature | 2 | 2025 | 622 | 0.140 |
Why?
| | Asparagine | 1 | 2018 | 34 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 861 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2021 | 227 | 0.140 |
Why?
| | Phospholipids | 1 | 2019 | 215 | 0.130 |
Why?
| | Carnitine | 1 | 2018 | 91 | 0.130 |
Why?
| | Feces | 1 | 2021 | 496 | 0.130 |
Why?
| | Mental Health | 1 | 2024 | 779 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1888 | 0.130 |
Why?
| | Comorbidity | 1 | 2023 | 1665 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2022 | 901 | 0.130 |
Why?
| | Economic Development | 1 | 2017 | 2 | 0.130 |
Why?
| | Smoking | 1 | 2025 | 1486 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 224 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 3 | 2026 | 3926 | 0.130 |
Why?
| | Mass Spectrometry | 2 | 2018 | 729 | 0.130 |
Why?
| | Energy Intake | 3 | 2025 | 507 | 0.130 |
Why?
| | Pediatrics | 3 | 2024 | 1124 | 0.130 |
Why?
| | Sleep | 1 | 2024 | 896 | 0.120 |
Why?
| | Risk Assessment | 2 | 2024 | 3712 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2021 | 536 | 0.120 |
Why?
| | Energy Metabolism | 2 | 2021 | 930 | 0.120 |
Why?
| | Snacks | 2 | 2015 | 23 | 0.120 |
Why?
| | Health Promotion | 1 | 2023 | 786 | 0.120 |
Why?
| | Dietary Fats | 2 | 2018 | 307 | 0.120 |
Why?
| | Mexican Americans | 1 | 2017 | 119 | 0.120 |
Why?
| | Prehypertension | 1 | 2015 | 27 | 0.110 |
Why?
| | Trans Fatty Acids | 1 | 2015 | 5 | 0.110 |
Why?
| | Glucose | 1 | 2021 | 1053 | 0.110 |
Why?
| | Risk | 1 | 2018 | 920 | 0.110 |
Why?
| | Developing Countries | 1 | 2017 | 312 | 0.110 |
Why?
| | Pregnancy Trimesters | 1 | 2014 | 20 | 0.110 |
Why?
| | Anxiety | 1 | 2022 | 1125 | 0.110 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2015 | 102 | 0.110 |
Why?
| | Cognition | 1 | 2023 | 1292 | 0.110 |
Why?
| | Body Weights and Measures | 1 | 2014 | 37 | 0.110 |
Why?
| | Prognosis | 3 | 2021 | 4351 | 0.110 |
Why?
| | Urban Population | 1 | 2017 | 497 | 0.100 |
Why?
| | Aging | 2 | 2023 | 1996 | 0.100 |
Why?
| | Los Angeles | 1 | 2013 | 73 | 0.100 |
Why?
| | New York City | 1 | 2013 | 89 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 568 | 0.100 |
Why?
| | Epigenomics | 2 | 2024 | 124 | 0.100 |
Why?
| | Mitochondria | 1 | 2020 | 997 | 0.100 |
Why?
| | Carbonated Beverages | 1 | 2013 | 16 | 0.100 |
Why?
| | Dietary Sucrose | 1 | 2013 | 49 | 0.100 |
Why?
| | Iron Overload | 1 | 2013 | 19 | 0.090 |
Why?
| | Food, Fortified | 1 | 2013 | 43 | 0.090 |
Why?
| | Ferritins | 1 | 2012 | 69 | 0.090 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2013 | 61 | 0.090 |
Why?
| | Vitamin A | 1 | 2012 | 60 | 0.090 |
Why?
| | Animals | 6 | 2021 | 38107 | 0.090 |
Why?
| | Sweden | 1 | 2012 | 114 | 0.090 |
Why?
| | Maternal Age | 1 | 2012 | 129 | 0.090 |
Why?
| | CpG Islands | 2 | 2024 | 175 | 0.090 |
Why?
| | Vitamin B 12 | 1 | 2012 | 140 | 0.090 |
Why?
| | Bronchial Neoplasms | 1 | 2011 | 15 | 0.080 |
Why?
| | Folic Acid | 1 | 2012 | 197 | 0.080 |
Why?
| | Aged | 2 | 2025 | 26432 | 0.080 |
Why?
| | Particulate Matter | 2 | 2025 | 328 | 0.080 |
Why?
| | Immunization Programs | 1 | 2012 | 194 | 0.080 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2013 | 269 | 0.080 |
Why?
| | Iron | 1 | 2012 | 359 | 0.080 |
Why?
| | Diet Surveys | 2 | 2021 | 89 | 0.070 |
Why?
| | Obesity, Morbid | 1 | 2013 | 287 | 0.070 |
Why?
| | Zinc | 1 | 2012 | 310 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2011 | 259 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2023 | 3647 | 0.070 |
Why?
| | SRS-A | 1 | 1987 | 17 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2921 | 0.070 |
Why?
| | Disease Progression | 1 | 2015 | 2867 | 0.070 |
Why?
| | Medicaid | 1 | 2012 | 477 | 0.070 |
Why?
| | Bronchial Provocation Tests | 1 | 1987 | 46 | 0.070 |
Why?
| | Prednisolone | 1 | 1987 | 65 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6073 | 0.060 |
Why?
| | Muscles | 2 | 2022 | 330 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 881 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2022 | 17438 | 0.060 |
Why?
| | Alberta | 1 | 2025 | 25 | 0.060 |
Why?
| | Bangladesh | 1 | 2026 | 64 | 0.060 |
Why?
| | Nitrogen Dioxide | 1 | 2025 | 45 | 0.060 |
Why?
| | Procollagen | 1 | 2025 | 24 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3416 | 0.050 |
Why?
| | Metabolic Networks and Pathways | 1 | 2026 | 175 | 0.050 |
Why?
| | Infant, Low Birth Weight | 1 | 2026 | 154 | 0.050 |
Why?
| | Mass Screening | 1 | 2013 | 1307 | 0.050 |
Why?
| | Ozone | 1 | 2025 | 116 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 1408 | 0.050 |
Why?
| | Collagen Type I | 1 | 2025 | 144 | 0.050 |
Why?
| | Canada | 1 | 2025 | 432 | 0.050 |
Why?
| | Hot Flashes | 1 | 2025 | 92 | 0.050 |
Why?
| | Esters | 1 | 2024 | 71 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2011 | 927 | 0.050 |
Why?
| | Academic Success | 1 | 2023 | 31 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 179 | 0.050 |
Why?
| | Parity | 1 | 2023 | 113 | 0.050 |
Why?
| | Accelerometry | 1 | 2023 | 124 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 40 | 0.050 |
Why?
| | Oxylipins | 1 | 2023 | 47 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 612 | 0.050 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2022 | 15 | 0.040 |
Why?
| | Starch | 1 | 2022 | 22 | 0.040 |
Why?
| | Life Style | 2 | 2016 | 496 | 0.040 |
Why?
| | Longevity | 1 | 2023 | 179 | 0.040 |
Why?
| | Food | 1 | 2022 | 149 | 0.040 |
Why?
| | Allergens | 1 | 2024 | 390 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2022 | 154 | 0.040 |
Why?
| | Bone Density | 1 | 2025 | 494 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2025 | 693 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1331 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8391 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2022 | 145 | 0.040 |
Why?
| | Parents | 2 | 2024 | 1394 | 0.040 |
Why?
| | Cardiology | 1 | 2024 | 363 | 0.040 |
Why?
| | Leukocytes | 1 | 2022 | 301 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 215 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2020 | 9 | 0.040 |
Why?
| | Louisiana | 1 | 2020 | 30 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2021 | 151 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 340 | 0.040 |
Why?
| | Host-Parasite Interactions | 1 | 2021 | 109 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 426 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2020 | 90 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2021 | 190 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 731 | 0.040 |
Why?
| | Eating | 1 | 2022 | 386 | 0.040 |
Why?
| | Telomere | 1 | 2022 | 300 | 0.040 |
Why?
| | Genitalia | 1 | 2018 | 32 | 0.030 |
Why?
| | Edible Grain | 1 | 2018 | 45 | 0.030 |
Why?
| | Public Health | 1 | 2023 | 574 | 0.030 |
Why?
| | Menarche | 1 | 2018 | 53 | 0.030 |
Why?
| | Quality of Life | 2 | 2025 | 3200 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2021 | 531 | 0.030 |
Why?
| | Cities | 1 | 2018 | 140 | 0.030 |
Why?
| | Meat | 1 | 2018 | 62 | 0.030 |
Why?
| | Testis | 1 | 2018 | 158 | 0.030 |
Why?
| | Social Class | 1 | 2019 | 260 | 0.030 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 146 | 0.030 |
Why?
| | Breast | 1 | 2018 | 155 | 0.030 |
Why?
| | Dietary Proteins | 1 | 2018 | 135 | 0.030 |
Why?
| | Autoimmunity | 1 | 2023 | 925 | 0.030 |
Why?
| | Lactation | 1 | 2018 | 193 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 453 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1730 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2016 | 91 | 0.030 |
Why?
| | Linoleic Acid | 1 | 2015 | 44 | 0.030 |
Why?
| | Oleic Acid | 1 | 2015 | 40 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2015 | 55 | 0.030 |
Why?
| | Vitamin D | 1 | 2018 | 402 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1143 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 858 | 0.030 |
Why?
| | Notophthalmus viridescens | 1 | 1993 | 1 | 0.030 |
Why?
| | Radio | 1 | 2013 | 1 | 0.030 |
Why?
| | Salamandridae | 1 | 1993 | 33 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2018 | 587 | 0.020 |
Why?
| | Tanzania | 1 | 2013 | 76 | 0.020 |
Why?
| | Consumer Health Information | 1 | 2013 | 44 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1575 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2488 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1993 | 534 | 0.020 |
Why?
| | Information Systems | 1 | 2012 | 58 | 0.020 |
Why?
| | Acclimatization | 1 | 1993 | 169 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1763 | 0.020 |
Why?
| | Reminder Systems | 1 | 2012 | 149 | 0.020 |
Why?
| | Models, Biological | 1 | 2018 | 1761 | 0.020 |
Why?
| | Models, Statistical | 1 | 2014 | 669 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 302 | 0.020 |
Why?
| | Digestive System Surgical Procedures | 1 | 2011 | 115 | 0.020 |
Why?
| | Chemoradiotherapy | 1 | 2011 | 238 | 0.020 |
Why?
| | Data Collection | 1 | 2012 | 650 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 693 | 0.020 |
Why?
| | Rural Population | 1 | 2013 | 677 | 0.020 |
Why?
| | Airway Resistance | 1 | 1987 | 38 | 0.020 |
Why?
| | Vaccines | 1 | 2012 | 389 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 11821 | 0.010 |
Why?
| | Phosphocreatine | 1 | 1993 | 44 | 0.010 |
Why?
| | Phosphates | 1 | 1993 | 175 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 543 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1993 | 494 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1993 | 627 | 0.010 |
Why?
| | Temperature | 1 | 1993 | 635 | 0.000 |
Why?
|
|
Perng's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|